News coverage about BIO-TECHNE (NASDAQ:TECH) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BIO-TECHNE earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.7523385509056 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
A number of research firms have weighed in on TECH. Zacks Investment Research cut BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. Deutsche Bank dropped their price objective on BIO-TECHNE from $167.00 to $165.00 and set a “buy” rating on the stock in a report on Thursday, May 3rd. Leerink Swann set a $160.00 price objective on BIO-TECHNE and gave the stock a “buy” rating in a report on Thursday, May 3rd. ValuEngine raised BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, BidaskClub raised BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a report on Friday, March 16th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $150.83.
Shares of NASDAQ TECH traded up $1.27 during midday trading on Tuesday, reaching $162.19. 199,873 shares of the company were exchanged, compared to its average volume of 178,147. The company has a quick ratio of 4.30, a current ratio of 5.55 and a debt-to-equity ratio of 0.37. BIO-TECHNE has a 1 year low of $109.12 and a 1 year high of $162.55. The firm has a market cap of $6.00 billion, a P/E ratio of 47.05, a P/E/G ratio of 2.63 and a beta of 0.71.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported $1.21 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.07. The firm had revenue of $164.00 million during the quarter, compared to the consensus estimate of $163.43 million. BIO-TECHNE had a net margin of 18.29% and a return on equity of 14.75%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.97 earnings per share. analysts anticipate that BIO-TECHNE will post 4.05 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, May 25th. Investors of record on Monday, May 14th were given a $0.32 dividend. The ex-dividend date of this dividend was Friday, May 11th. This represents a $1.28 dividend on an annualized basis and a yield of 0.79%. BIO-TECHNE’s payout ratio is currently 37.43%.
In related news, CEO Charles R. Kummeth sold 8,000 shares of the firm’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $160.00, for a total value of $1,280,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.40% of the stock is owned by company insiders.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Receive News & Ratings for BIO-TECHNE Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BIO-TECHNE and related companies with MarketBeat.com’s FREE daily email newsletter.